MYC gene rearrangements detected by interphase fluorescence in situ hybridization in diffuse large B-cell lymphomas

J A Misharina1, V V Sitko2, S V Klymenko2

  • 1National Medical University O.O. Bohomolets, boulevard T.Shevchenko, 13, Kiev, 01601, Ukraine.

Insights

Interphase fluorescence in situ hybridization (I-FISH) accurately identifies MYC and IGH gene translocations in diffuse large B-cell lymphoma (DLBCL). This molecular-cytogenetic analysis aids in lymphoma diagnosis, prognosis, and treatment, particularly for refractory cases.

Area of Science:

  • Hematology
  • Oncology
  • Cytogenetics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most prevalent B-cell non-Hodgkin lymphoma (B-NHL).
  • Chromosomal translocations, particularly MYC gene dysregulation, are key genetic aberrations in B-cell lymphomas, including Burkitt's lymphoma.
  • Accurate diagnosis and prognostication are crucial for effective DLBCL management.

Purpose of the Study:

  • To enhance the diagnostic accuracy of DLBCL.
  • To identify specific chromosomal abnormalities, including MYC gene translocations (t(8;14)(q24;q32)), in lymphoma cells.
  • To evaluate the utility of tri-color interphase fluorescence in situ hybridization (I-FISH) for detecting these abnormalities.

Main Methods:

  • Lymph node biopsy specimens from 17 DLBCL and 3 Burkitt's lymphoma patients were analyzed.
  • Paraffin-embedded tissues were subjected to I-FISH analysis using a commercial Vysis IGH/MYC, CEP 8 tri-color probe.
  • The study focused on identifying rearrangements of the MYC gene and immunoglobulin heavy chain (IGH) gene.

Main Results:

  • MYC and IGH gene translocations were detected in 4 out of 20 patients.
  • The I-FISH method successfully identified MYC and IGH gene rearrangements in paraffin-embedded lymphoma tissue.
  • Molecular-cytogenetic abnormalities were found in 8 out of 20 B-cell lymphoma patients.

Conclusions:

  • I-FISH is an effective method for identifying MYC and IGH gene rearrangements in lymphoma tissues.
  • Detecting these molecular-cytogenetic abnormalities aids in verifying DLBCL diagnosis.
  • This approach can improve clinical course prediction and therapeutic strategies, especially for refractory lymphoma cases.